XTL BIOPHARMACEUTICALS LTD XTLB

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS—

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue —$451.0K————————
SG&A —————$910.0K$807.0K$755.0K——
Operating income —-$2.2M-$765.0K-$880.0K-$1.0M-$948.0K-$842.0K-$793.0K-$1.2M-$2.6M
Net income —-$1.0M-$1.8M-$1.3M$435.0K-$3.0M-$763.0K$3.6M-$781.0K-$2.5M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Short-term investments —————$2.4M$2.3M———
Total assets —$5.8M$2.4M$4.2M$6.6M$6.5M$7.2M$8.6M$6.6M$3.0M
Total equity —$5.4M$2.2M$4.0M$5.3M$3.6M$6.5M$7.3M$3.6M$2.7M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-073831.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Total equity
  • R&D
  • Total current liabilities
  • Receivables
Total equity, R&D, Total current liabilities, Receivables by fiscal year, in US dollars The same figures are in the table below this chart. 0 2M 4M 6M 8M Total equity, FY2016: 2.7M Total equity, FY2017: 3.6M Total equity, FY2018: 7.3M Total equity, FY2019: 6.5M Total equity, FY2020: 3.6M Total equity, FY2021: 5.3M Total equity, FY2022: 4M Total equity, FY2023: 2.2M Total equity, FY2024: 5.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Total equity $2.7M $3.6M $7.3M $6.5M $3.6M $5.3M $4.0M $2.2M $5.4M —
R&D — — — — — — — — — —
Total current liabilities — — — — — — — — — —
Receivables — — — — — — — — — —

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
AKTX Akari Therapeutics Plc $1.79T — —
LLY ELI LILLY & Co $1.08T 50.1x 44.7%
JNJ JOHNSON & JOHNSON $663.28B 25.0x 6.0%
ONC BeOne Medicines Ltd. $529.55B 1,885.6x 40.2%
ABBV AbbVie Inc. $453.19B 108.7x 8.6%
MRK Merck & Co., Inc. $370.89B 20.6x 1.3%
ABT ABBOTT LABORATORIES $188.69B 29.1x 5.7%
PFE PFIZER INC $162.16B 20.9x -1.6%